< BACK

 

Paul Gilson

 

Paul Gilson is a medical device entrepreneur. He raised >€100 million of VC and Corporate funds in UK, US, EU and Ireland. He works with Veryan Medical, an Imperial College spinout acquired by Otsuka in 2018, developing next generation endovascular products. 

Previously, he was a co-founder and General Manager of MedNova and was responsible for the development of novel stroke treatment technologies. The products received CE Mark and PMA approval. The company was acquired by Abbott Laboratories in 2007. 
 

In addition, Paul co-founded Novate Medical, was CEO initially, then CSO. Novate developed an innovative IVC Filter which was FDA 510k cleared and CE marked. The company was acquired in 2018 by BTG and in turn by BSCI in 2019.

He was Chairman of Embo Medical, a spinout from the NUIG/Stanford Bio-Innovate Program which was acquired by C.R. BARD in 2015.
 

Paul holds board positions with ProVerum, Bluedrop Medical, LaNua Medical, Selio Medical, InVera Medical and Ostoform.
 

Prior to his experience in start-up companies, he held several senior roles in Operations, Product Development and R&D. He was Director of R&D for Bard Cardiology where he led the development of interventional cardiovascular devices. Paul has extensive experience in licensing and IP portfolio management and is the holder of more than 60 US patents for bio-materials, surgical and cardiovascular products.
 

Paul has been appointed Adjunct Professor in the School of Science and Engineering at the University of Galway where he works with the BioInnovate Fellowship Program.